- Home
- ONVO vs GRI Comparison
ONVO vs GRI Comparison
Compare ONVO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- GRI
- Stock Information
- Founded
- ONVO 2007
- GRI 2018
- Country
- ONVO United States
- GRI United States
- Employees
- ONVO N/A
- GRI N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ONVO Health Care
- GRI Health Care
- Exchange
- ONVO Nasdaq
- GRI Nasdaq
- Market Cap
- ONVO 5.6M
- GRI 6.1M
- IPO Year
- ONVO N/A
- GRI N/A
- Fundamental
- Price
- ONVO $0.45
- GRI $0.91
- Analyst Decision
- ONVO
- GRI Strong Buy
- Analyst Count
- ONVO 0
- GRI 2
- Target Price
- ONVO N/A
- GRI $11.50
- AVG Volume (30 Days)
- ONVO 214.6K
- GRI 365.9K
- Earning Date
- ONVO 02-06-2025
- GRI 11-14-2024
- Dividend Yield
- ONVO N/A
- GRI N/A
- EPS Growth
- ONVO N/A
- GRI N/A
- EPS
- ONVO N/A
- GRI N/A
- Revenue
- ONVO $103,000.00
- GRI N/A
- Revenue This Year
- ONVO $59.08
- GRI N/A
- Revenue Next Year
- ONVO $18.24
- GRI N/A
- P/E Ratio
- ONVO N/A
- GRI N/A
- Revenue Growth
- ONVO N/A
- GRI N/A
- 52 Week Low
- ONVO $0.32
- GRI $0.30
- 52 Week High
- ONVO $1.74
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- ONVO 59.27
- GRI 61.47
- Support Level
- ONVO $0.42
- GRI $0.71
- Resistance Level
- ONVO $0.52
- GRI $0.82
- Average True Range (ATR)
- ONVO 0.05
- GRI 0.07
- MACD
- ONVO 0.01
- GRI 0.01
- Stochastic Oscillator
- ONVO 65.53
- GRI 94.04
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.